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Genomic instability is a well-known hallmark of cancer. Recent genome sequencing studies have led to the
identification of novel phenomena called chromothripsis and chromoanasynthesis in which complex genomic
rearrangements are thought to be derived from a single catastrophic event rather than by several incremental steps.
A new term chromoanagenesis or chromosomal rebirthwas coined recently to group these two one-step catastrophic
events together. These phenomena suggest an evolutionary modality for cancer cells to circumvent individual
mutational events with one simultaneous shattering of chromosomes resulting in the random reassembling of
segmented genetic material to form complex derivative chromosomes. We report a case of possible chromoanagen-
esis in a patient with diffuse large B-cell lymphoma. Chromosome analysis from the biopsy showed a complex
karyotype with multiple numerical and structural rearrangements including a translocation of chromosomes 3 and 7
involving the BCL6 gene region, with the derivative chromosome further rearranging with chromosomes 14, 7, and 22
with involvement of the IGH gene region. Fluorescence in situ hybridization studies confirmed these findings.
Chromosomal microarray studies showed multiple complex copy number variations including a chromosome 12
abnormality, the complexity of which appears to suggest the phenomenon of chromoanagenesis. Our case further
illustrates that lymphomagenesis can be complex and may arise from a catastrophic event resulting in multiple
complex chromosome rearrangements.
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Genomic instability is a well-described distinctive feature of cancer.
Thus, uncovering pathways describing acceleration of such instability
is not surprising. Previously, genomic instability was thought to arise
through a gradual multistep process resulting in sequential
accumulation of many independent genomic lesions [1–3]. Such
lesions may include somatic point mutations, copy number
alterations such as chromosomal gains and losses, and balanced
structural rearrangements such as translocations and inversions [4–7].
Although there is well-established evidence for this gradualism in
cancer development, there were reasons to hypothesize that cancer
cells might acquire all genomic lesions at once to circumvent the
defensive responses from the genome. Recent genome sequencing
studies have led to identification of three novel phenomena called
chromothripsis, chromoanasynthesis, and chromoplexy [8–11]. Although
the underlying mechanisms of these novel phenomena are not knownand were hypothesized to be different, the resulting complex genomic
rearrangements are thought to be derived from a single catastrophic
event rather than by several incremental steps [12–16]. Holland and
Cleveland [17] suggested the term chromoanagenesis or chromosomal
rebirth to group these one-step catastrophic events together. We
224 B-Cell Lymphoma and Chromoanagenesis Ortega et al. Neoplasia Vol. 18, No. 4, 2016report a case of possible chromoanagenesis in a patient with
diffuse large B-cell lymphoma (DLBCL) arising from follicular
lymphoma (FL).
Material and Methods
Case Report
A 59-year-old Caucasian woman with history of hypothyroidism
presented to the clinic with rapidly enlarging goiter causing significant
dyspnea. She noticed swelling in the neck 2 months before presenting
to the clinic. A computed tomographic scan showed extensive
infiltration and enlargement of the thyroid gland with significant
effect on the trachea, limited to 4.3 mm in width at the thoracic inlet.
Thyroid biopsy showed sheets of large dysplastic B-cells, diagnostic of
DLBCL. The neoplastic B-cells expressed CD10, BCL6, MUM1,
and BCL2 and lacked expression of CD30, Cyclin D1, and EBER.
Flow cytometric analysis also showed the clonal B-cells (45% of total
cells) expressed CD19, CD20, and surface lambda light chain and
lacked CD45. Background nodular follicular dendritic meshwork
(CD21+) suggested that the DLBCL may have arisen from FL. Bone
marrow biopsy was normal and unremarkable.
Chromosome Analysis
Cytogenetic analysis was carried out on biopsy tissue. Culture
initiation, maintenance, and harvest were done using standard methods
[18]. Chromosomes were G-banded [19] and then analyzed using a
Cytovision image analysis system (Applied Imaging, Santa Clara, CA).
Fluorescence In Situ Hybridization (FISH)
FISH was performed on the cultured biopsy specimen using
directly labeled break-apart probe BCL6 (5’ labeled in spectrum
orange and 3’ in spectrum green); dual-color, dual-fusion transloca-
tion probe IGH/BCL2 (IGH labeled in spectrum green and BCL2 in
spectrum orange); and whole chromosome paint probes for
chromosomes 7 (labeled in spectrum green), 14 (spectrum orange),
and 12 (spectrum green) (Cytocell, Windsor, CT). The probes were
hybridized to interphase nuclei and metaphase chromosomes using
standard procedures, followed by counterstaining with 4,6-diamidino-
2-phenylindole, and then analyzed using a Cytovision image analysis
system (Applied Imaging, Santa Clara, CA). For interphase analysis, a
minimum of 100 nuclei were scored, and for metaphase analysis, a
minimum of 10 metaphases were scored.
Single Nucleotide Polymorphism (SNP)
Oligonucleotide Microarray
Given the complex nature of the abnormalities observed,
chromosome microarray studies were carried out using Affymetrix
CytoScan HD microarray. The Affymetrix CytoScan HD Assay uses
a high density combined CGH and SNP array platform, which
assesses approximately 2,696,550 markers, including approximately
750,000 SNP markers. Each oligonucleotide is approximately 25 bp
long. Intragenic probe spacing is approximately 1 probe every 880 bp,
and intergenic probe spacing is approximately 1 probe every 1700 bp.
To perform the assay, gDNA is digested with the Nsp1 restriction
enzyme and digested DNA is then ligated to Nsp1 adapters. The
ligation product is then amplified via polymerase chain reaction to
produce amplicons in the 200- to 1100-bp range. The amplicons are
then purified and digested with DNAse I to produce 25- to 125-bp
fragments. The fragments are end-labeled with a modified biotinylated
base, and the sample is then hybridized to the array. The array is washedand then stained with a streptavidin-coupled dye and a biotinylated
antistreptavidin antibody. The array is then scannedwith theGeneChip
Scanner, and the signal intensity for each marker is assessed. Using
the Chromosome Analysis Suite (ChAs 3.0) software, the signal for
the sample is then compared with a reference set, which is based on
the average of more than 400 samples. Differences in signal between the
sample and reference are expressed as a log2 ratio and represent relative
intensity for each marker. A discrete copy number value is determined
from the relative intensity data and is displayed. Genotype information
for the SNP markers is visualized with the Allele Track [20].
Results
Cytogenetic Studies
Chromosome analysis from the biopsy tissue showed a complex
hyperdiploid karyotype with multiple structural and numerical
abnormalities including rearrangements involving the 3q and 14q
regions. Based on G-banded analysis of 20 cells, the karyotype was
interpreted as 51~56,XX,+X,+X,+2,t (3;7)(q29;p11.2) ,
der(7)t(3;7)t(14;7;22)(q32;p11.2;q12),+der(7)t(14;7;22),
der(8) t (8;18)(p12;q21) ,+der(9)t (5 ;9) (q13;q22) ,+13,der
(14)t(14;7;22),+21,+1~4r[cp20] (Figure 1). Chromosome analysis
of the bone marrow sample showed a normal female karyotype.
FISH
FISH studies with BCL6 break-apart probe showed BCL6 gene
rearrangement in 36.5% of the nuclei (Figure 2, A and B), and with
dual-color, dual-fusion IGH/BCL2 probes showed IGH gene
rearrangement in 41.2% of the nuclei (Figure 2, C and D) and an
additional copy of the BCL2 gene region in 7% of the nuclei
(Figure 2, E and F). Metaphase FISH analysis showed that the
5’BCL6 remained on chromosome 3q whereas the 3’ BCL6 was
translocated to a chromosome 7. Similarly, metaphase analysis
showed complex structural rearrangement involving the IGH gene
region with parts of IGH being translocated to chromosome 7 and
also chromosome 22 (Figure 2G). These results confirm the complex
nature of the derivative chromosome 7 observed on chromosome
analysis. FISH analysis with whole chromosome paints confirmed the
t(3;7) (Figure 2H) and that the ring chromosome was derived from a
chromosome 12 (Figure 2I).
Chromosomal Microarray Studies
The results showed multiple abnormalities interpreted as
arr(1-22,X)cx. The abnormalities observed included mosaic gain
(14.7%) of chromosome 2, mosaic gain (40%) of chromosome
5q11.2q35.3, mosaic gain (45%) of chromosome 7p22p12.3, mosaic
loss (7%) of chromosome 7p12.3q36.3, multiple aberrations
indicating chromoanagenesis on chromosome 12, mosaic gain
(10%) of chromosome 13, mosaic gain (21%) of chromosome 21,
and mosaic gain (21%) of chromosome X (Figure 3, A–G). Although
the IGH gene region on chromosome 14 underwent complex
structural rearrangements, array studies did not show any imbalance
involving this region, thus indicating that, despite the complex
nature, the IGH rearrangements are balanced.
Based on these results, we propose that simultaneous breaks on
chromosomes 3, 7, 14, and 22 with concurrent exchange and
reassembly of the broken segments lead to a complex chromosomal
rearrangement resulting in several derivative chromosomes: a der(3)
consisting of 3pter-q29 and 7pter-p11.2, a der(7) consisting of
7p11.2-qter, 3q29-qter and 14q32-qter, a der(14) consisting of
Figure 1. Karyotype from thyroid biopsy showing complex chromosome abnormalities.
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and 14q32-qter (Figure 4). Of the one to four ring chromosomes
observed on karyotypic analysis, based on the array data, the most
commonly observed ring chromosome was derived from chromo-
some 12 (present in more than 10 cells), whereas 2 smaller ring
chromosomes (Figure 3C) were interpreted as originating from 7pFigure 2. FISH analysis showing multiple gene rearrangements.
rearrangement in interphase nuclei. (C) IGH gene rearrangement o
(E) BCL2 gene rearrangement in metaphase. (F) BCL2 gene rearrange
gene rearrangement. (H) Whole chromosome paint 7 and 14 showing
chromosome is derived from a chromosome 12.(present in less than 10 cells) and the remaining 1 ring chromosome
(Figure 1) derived from chromosome 13 (present in less than 3
cells). The array and FISH results suggested that simultaneous
shattering of chromosome 12 with subsequent duplication and
triplication of interstitial segments and loss of telomeric regions lead
to the ring formation (Figure 4).(A) BCL6 gene rearrangement on metaphase. (B) BCL6 gene
n metaphase. (D) IGH gene rearrangement in interphase nuclei.
ment in interphase nuclei. (G) Schematic showing the complex IGH
the t(3;7). (I) Whole chromosome paint 12 confirming that the ring
Figure 3. SNP microarray showing the complex abnormalities observed. (A) Mosaic gain of chromosome 2 (blue arrow). (B) Mosaic gain
of chromosome 5q11.2q35.3 (blue arrow). (C) Mosaic gain of chromosome 7p22p12.3 (blue arrow) and mosaic loss of chromosome
7p12.3q36.3 (red arrow). (D) Multiple gains and losses of chromosome 12. Mosaic LOH for 12p13.33p12.3 (red line and arrow). Mosaic
LOH for 12q21.1q24.33 (red line and arrow). Four copies of 12p12.3 (green line and arrow). Three to four copies of mosaic gain
12p12.3p12.1 (purple line and arrow). Two to three copies of 12p12.1q14.3 (blue line and arrow) and four to five copies of mosaic gain
12q14.3q21.1 (pink line and arrow). (E) Mosaic gain on chromosome 13 (blue arrow). (F) Mosaic gain of chromosome 21. (G) Mosaic gain
of X chromosome.
Figure 4. Schematic representation of complex rearrangements (A) involving chromosomes 3, 7, 14, and 22. (B) Multiple breaks and
reassembly leading to formation of r(12).
226 B-Cell Lymphoma and Chromoanagenesis Ortega et al. Neoplasia Vol. 18, No. 4, 2016
Neoplasia Vol. 18, No. 4, 2016 B-Cell Lymphoma and Chromoanagenesis Ortega et al. 227Discussion
DLBCL is the most common malignant lymphoma subtype in adults,
accounting for roughly 40% of all cases [21]. DLBCL is characterized
by remarkable heterogeneity, affecting several aspects of the disease.
This heterogeneity can at least partially be explained by recently
identified molecularly defined subtypes [22]. DLBCL can be
classified as de novo or as secondary, transformed DLBCL emanating
from an indolent lymphoma, most commonly FL. The distinction
between transformed and de novo DLBCL is based on the
morphological demonstration of low–malignancy grade lymphoma
such as FL either before or simultaneous to the DLBCL. In our case,
the presence of background nodular follicular dendritic meshwork
(CD21+) suggested that the DLBCL may have arisen from FL.
Several secondary genetic abnormalities have been reported to be
associated with this histological transformation of FL, including gene
rearrangements involving MYC, BCL6, and BCL2 and mutations of
TP53 tumor suppressor gene [23]. In addition to these specific
genetic changes, transformation has been associated with cytogenetic
alterations such as loss or gain of whole chromosomes, deletions, and
amplifications [23]. One of such frequent gains is chromosome 18q
including the BCL2 gene locus which was also seen in 7% of cells in
our case. Other changes acquired exclusively upon transformation
included the gain of a segment on chromosome 12 from pter to q12.
Trisomy 12 is frequently seen in many B-cell malignancies, with the
common region of amplification delineated to 12q12q15 [24]. Copy
number gains at 12q12q14 were reported exclusively in DLBCL
transformed from FL [25]. In accordance with published studies
showing that the 12q amplicon is highly complex and exhibits
discontinuous regions of amplification in high-grade lymphomas
[26], our case showed multiple and complex rearrangements
involving the chromosome 12 with mosaic loss and gain of three to
five copies of chromosome 12, especially overlapping the 12q12q14
region. Karyotypic analysis also showed that transformed DLBCLs
are cytogenetically more unstable, thereby resulting in multiple
numerical and structural alterations. The complex structural
rearrangement involving chromosomes 3, 7, 14, and 22 (Figure 4)
is an indication of such underlying instability in the genome of these
transformed DLBCLs. In addition, several studies have shown
overrepresentation of X chromosome in FL and DLBCL [25], and
gain of an X chromosome was also seen in our case.
Gene amplification and loss have an important role in the
activation of oncogenes and inactivation of tumor suppressor genes.
The mechanism underlying the formation of the amplified DNA
segment (amplicon) is poorly understood. Microsatellite repeat
analysis studies have shown that these amplicons have complex
structures with amplified loci interspersed with nonamplified loci
[26]. The structure of these amplicons owes its complexity not only to
amplifications but also to losses of DNA segments and enables
simultaneous activation of cellular oncogenes and inactivation of
tumor suppressor genes. It is a common assumption that chromo-
somal gains and losses exert “dosage effects” on the expression of at
least some of the genes within these regions; however, confirmation of
this hypothesis especially in the process of FL transformation to
DLBCL had been limited. The recently identified phenomenon of
“chromoanagenesis” might explain the complex nature of these
amplicons because it is known to cause catastrophic shattering of
chromosomes or chromosome segments giving rise to chromosomal
gains and losses in a single event. The hallmark of chromothripsis is
said to be that the catastrophic event involves just a few regions in thegenome giving rise to an extremely high local rearrangement density.
We propose that the complex chromosome 12 rearrangement in our
patient with approximately six breakpoints resulting in multiple gains
and losses ultimately leading to the ring formation (Figure 4) is the
result of chromothripsis rather than chromoanasynthesis because
chromoanasynthesis is reported to occur more frequently in distal
parts of chromosome arms and is more common in germline than
somatic cells [9,27]. A second hallmark of chromothripsis is random
shattering of chromosomes and reassembly leading to highly mosaic
chromosomes from small and large chromosome pieces derived from
diverse locations and stitched together in all possible combinations
[28]. In our case, the complex rearrangement involving chromosomes
3, 7, 14, and 22 indicates this random shattering and reassembly.
Because chromoanasynthesis is reported to be mostly observed within
a single chromosome [9,29], this complex rearrangement in our case
most probably is the result of chromothripsis and not chromoana-
synthesis. The third hallmark of chromothripsis is said to be presence
of two copy number states with the lower number copy state often
displaying loss of heterozygosity [28]. In our case, the mosaic loss of
heterozygosity on chromosome 12 short and long arms observed with
microarray studies is in accordance with this chromothripsis
signature. The ability to detect chromothripsis in cancer is limited
by the methodology used. For example, the incidence of chromo-
thripsis is reported to be low using SNP-based microarray studies,
whereas studies using whole genome sequencing method showed a
much higher frequency of chromothripsis in cancer [28].
One of the significant limitations of our study is the lack of
sequencing data to confirm chromothripsis or chromoanasynthesis in
our patient. Lack of resources does not permit us to undertake
sequencing studies to confirm our hypothesis. Nevertheless, our
results and the rapid progression of disease provide reasonable
evidence of chromoanagenesis in our patient.
In summary, we report a patient with DLBCL possibly arising from
FL, and the complex chromosome abnormalities observed in our patient
suggest that chromoanagenesis might have led to the complex structural
rearrangements. Although several studies have documented multiple
structural and numerical chromosome abnormalities, especially in those
cases that have transformed from FL to DLBCL, the mechanism
resulting in such complex rearrangements has not been postulated. We
propose that chromoanagenesis might provide a possible explanation for
the chromosome instability and the associated poor prognosis in those
patients with transformation from FL to DLBCL.References
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